Navigation Links
Protein test detects early-stage, asbestos-related pulmonary cancer
Date:4/4/2011

ORLANDO, Fla. Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

In a blinded test performed under the auspices of the National Cancer Institute's Early Detection Research Network Biomarker Discovery Lab, the proteomic assay could detect 15 of 19 cases of malignant pleural mesothelioma that were in stage 1 or stage 2, making the test about 80 percent sensitive, a measure of how accurately a test can identify disease. In addition, the specificity of the test was 100 percent, meaning there were no false positives in this study.

Harvey I. Pass, M.D., director of the division of thoracic surgery and thoracic oncology at NYU Langone Medical Center and the NYU Cancer Institute in New York, and colleagues used the SomaLogic, Inc. aptamer proteomics platform to examine 170 blood samples from 90 patients diagnosed with malignant mesothelioma and 80 participants who had been exposed to asbestos. Three-fourths of the samples were used to derive 19 significant biomarkers for mesothelioma and the remaining 25 percent were used in the blinded test.

Malignant pleural mesothelioma is an aggressive, asbestos-related pulmonary cancer that is increasing in incidence. Experts believe this form of cancer will not peak for another 20 years due to a latency period of 20 to 40 years from asbestos exposure. It currently causes an estimated 15,000 to 20,000 deaths per year worldwide. Once diagnosed, the disease is usually fatal (within 14 months) because of the advanced stage that it is typically found. The goal of a diagnostic test such as this one is to find the cancer early enough to effectively treat it, according to Pass.

"The only patients that seem to benefit from therapy in mesothelioma are those that are found in stage 1, and this is only 10 to 15 percent of patients," he said. "Moreover, when found early, the magnitude of the operation necessary to reduce the burden of disease may be less, making the patient better able to cope if the disease recurs and the patient needs more aggressive therapy."

The research team tested the assay produced by SomaLogic, Inc. Its "Multiplex SOMAmer Assay" currently measures more than 1,000 proteins simultaneously from a sample of blood as small as 0.003 of a teaspoon, and can handle 300 samples a day, according to Pass. The assay uses SOMAmers chemically modified single-stranded DNA molecules that fold into different structures and bind specifically to target proteins to identify and quantify proteins across a broad range of concentrations.

According to Pass, this platform combines the best qualities of an immunoassay, and is able to find and quantify low abundance proteins secreted by tumor cells. Ongoing studies are refining the test and validating the results in other patient blood samples, according to Pass.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. New and Delicious, Almond Butter Filled, Cookie Bites With 35.7% Protein to Help Manage Weight and Build Muscle
2. Research highlights role of protein pair in obesity regulation
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Smithfield, United Food and Commercial Workers Union, and Food Networks Paula Deen to Deliver 150,000 Servings of Protein to San Francisco Food Bank
5. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
6. Protein Appears Key to Intestinal Balance
7. SIBLING proteins may predict oral cancer
8. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
9. Cells of aggressive leukemia hijack normal protein to grow
10. Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants
11. Proteins May Predict Spread of Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: